Neonatal-6-hydroxydopamine treatment: Model of susceptibility for self-mutilation in the lesch-nyhan syndrome

[1]  K. Shannak,et al.  Biochemical evidence of dysfunction of brain neurotransmitters in the Lesch-Nyhan syndrome. , 1981, The New England journal of medicine.

[2]  R. Watts,et al.  Clinical and biochemical studies on treatment of Lesch-Nyhan syndrome , 1974, Archives of disease in childhood.

[3]  B. Cooper,et al.  BIOCHEMICAL AND BEHAVIOURAL ALTERATIONS FOLLOWING 6-HYDROXYDOPAMINE ADMINISTRATION INTO BRAIN. , 1974, Biochemical pharmacology.

[4]  B. Cooper,et al.  Growth and behavioral changes in developing rats treated intracisternally with 6-hydroxydopamine: evidence for involvement of brain dopamine. , 1973, The Journal of pharmacology and experimental therapeutics.

[5]  B. Cooper,et al.  Alterations in consummatory behavior following intracisternal injection of 6-hydroxydopamine. , 1973, Pharmacology, biochemistry, and behavior.

[6]  O. Hornykiewicz.  Parkinson's disease: from brain homogenate to treatment. , 1973, Federation proceedings.

[7]  G. Breese,et al.  Developmental characteristics of brain catecholamines and tyrosine hydroxylase in the rat: effects of 6‐hydroxydopamine , 1972, British journal of pharmacology.

[8]  G. Breese,et al.  Effect of 6-hydroxydopamine on brain norepinephrine and dopamine evidence for selective degeneration of catecholamine neurons. , 1970, The Journal of pharmacology and experimental therapeutics.

[9]  J. Seegmiller,et al.  Enzyme Defect Associated with a Sex-Linked Human Neurological Disorder and Excessive Purine Synthesis , 1967, Science.

[10]  W. Nyhan,et al.  A FAMILIAL DISORDER OF URIC ACID METABOLISM AND CENTRAL NERVOUS SYSTEM FUNCTION. , 1964, The American journal of medicine.